Market Access UK pharma policy at a turning point: NICE threshold reform, ... The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
R&D The SPC waiver: How do we restore the intended balance betwe... Biosimilars promote cost-effective solutions to critical healthcare challenges.
Views & Analysis Huge scale of Brexit threat to Europe’s medicines supplies r... New survey reveals the huge task facing pharma in keeping medicines moving around Europe after Brexit.
News Trodelvy gets EU nod for first-line triple-neg breast cancer A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.